Abstract

Anxiety disorder is a well-recognized condition observed in subjects submitted to acute stress. Although the brain mechanisms underlying this disorder remain unclear, the available evidence indicates that oxidative stress and GABAergic dysfunction mediate the generation of stress-induced anxiety. Cannabinoids are known to be efficient modulators of behavior, given that the activation of the cannabinoid receptors type-1 (CB1 receptors) induces anxiolytic-like effects in animal models. In the present study, we aimed to describe the effects of the stimulation of the CB1 receptors on anxiety-like behavior, oxidative stress, and the GABA content of the brains of zebrafish submitted to acute restraint stress (ARS). The animals submitted to the ARS protocol presented evident anxiety-like behavior with increased lipid peroxidation in the brain tissue. The evaluation of the levels of GABA in the zebrafish telencephalon presented decreased levels of GABA in the ARS group in comparison with the control. Treatment with ACEA, a specific CB1 receptor agonist, prevented ARS-induced anxiety-like behavior and oxidative stress in the zebrafish brain. ACEA treatment also prevented a decrease in GABA in the telencephalon of the animals submitted to the ARS protocol. Overall, these preclinical data strongly suggest that the CB1 receptors represent a potential target for the development of the treatment of anxiety disorders elicited by acute stress.

Highlights

  • Anxiety disorder is a global public health problem (Alonso et al, 2018)

  • The trajectories of the two groups in the apparatus are shown in Figure 1A which, together with the data presented in Figure 1B indicates that zebrafish submitted to acute restraint stress (ARS) protocol spent less time on the top of the apparatus when compared with the control group

  • This anxiogenic effect was prevented by ACEA treatment which has increased the exploration of zebrafish on the top of apparatus in animals submitted to ARS when compared with non-treated animals exposed to acute stress

Read more

Summary

Introduction

Anxiety disorder is a global public health problem (Alonso et al, 2018). The World Health Organization (WHO) estimates that approximately one-third of the world’s population develops anxiety at some time, with many of the cases being triggered by traumatic events (Bandelow and Michaelis, 2015). There is good evidence that the pharmacological modulation of the GABAergic system can prevent the anxiety-like behavior induced by acute and chronic stress (Nuss, 2015; Assad et al, 2020; Farajdokht et al, 2020). Pro-oxidant events in the brain tissue are known to be closely associated with anxiety disorder elicited by post-traumatic events (Sousa et al, 2018). Based on these findings, it is reasonable to assume that compounds able to modulate GABAergic synapses and inhibit oxidative stress will have protective effects against anxiety disorder induced by acute stress

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call